Pharmafile Logo

tenofovir disproxil

- PMLiVE

Novo Nordisk expands cell therapy R&D, says type 1 diabetes cure a step closer

Company has reached milestone in stem cell therapy as it looks to broaden range beyond diabetes

- PMLiVE

Regeneron’s Dupixent and Praluent falls short

But CEO Len Schleifer says there’s time to fix that

- PMLiVE

Novo Nordisk fends off Lilly’s GLP-1 challenge in Q1

Insulin specialist bounces back with encouraging signs from Ozempic launch

- PMLiVE

Morning brief: Gilead partners with Verily, Roche expands 4DMT partnership and more

A rapid round up of pharma, biotech and healthcare news

Gilead Sciences

Gilead and Verily team up to map inflammatory diseases

Computational analysis could provide deeper understanding of disease

Sanofi reception

Sanofi’s latecomer PD-1 gets date for FDA verdict

While Keytruda extends its lead, Sanofi makes a late bid to enter PD-1 space

- PMLiVE

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

AstraZeneca, Roche and Gilead among companies one step closer to approval

- PMLiVE

Morning brief: Sanofi’s shaky start, pharma begins talks with UK government and more

Sanofi falling behind in Amgen cholesterol battleFirst quarter results from Sanofi show the company has got off to shaky start in 2018, including signs that it its PCKS9 inhibitor cholesterol...

Sanofi reception

Sanofi warns of difficult few months as diabetes sales slump

Dupixent sales fall compared to Q4 2017

- PMLiVE

Sanofi appoints ex-Roche Reed as new R&D head

John Reed to take up post after leaving Roche last month

Sanofi reception

Sanofi sells European generics to Advent for $2.4bn

The deal will create a new, independent European generics company

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links